MWNA
KURA icon

Marshall Wace North America’s Kura Oncology KURA Stock Holding History

Marshall Wace North America’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-28,897
Closed -$944K – 1646
2020
Q4 		$944K Buy
+28,897
New +$1.02M ﹤0.01% 958
2020
Q3 		– Sell
-31,934
Closed -$521K – 1355
2020
Q2 		$521K Buy
+31,934
New +$461K ﹤0.01% 916
2019
Q4 		– Sell
-7,952
Closed -$121K – 1446
2019
Q3 		$121K Sell
7,952
-61,717
-89% -$1.1M ﹤0.01% 1028
2019
Q2 		$1.37M Buy
+69,669
New +$1.16M 0.01% 658

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Marshall Wace North America's KURA Position: Q1 2021 in Review

Marshall Wace North America sold out of Kura Oncology (KURA) in Q1 2021, closing a stake of 28,897 shares — an estimated $944K sold.

Marshall Wace North America first reported a position in KURA in Q2 2019 and held it in 4 quarters. The position peaked at $1.37M in Q2 2019. 171 funds tracked by Wall St. Rank hold KURA as of Q1 2021.

  • Marshall Wace North America reported no remaining Kura Oncology position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 28,897 Kura Oncology shares in Q1 2021, an estimated $944K.
  • Marshall Wace North America first reported a position in Kura Oncology in Q2 2019 and held it in 4 quarters.
  • Marshall Wace North America's Kura Oncology position peaked at $1.37M in Q2 2019.
  • 171 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.